We disclosed a regio-selective C–H and N–H bond functionalization of indolines using alcohols in water via tandem dehydrogenation of N-heterocycles and alcohols. A diverse range of N- and C3-alkylated indolines/indoles were accessed utilizing a new cooperative iridium catalyst. The practical applicability of this methodology was demonstrated by the preparative-scale synthesis and synthesis of a psychoactive
FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG
申请人:Sato Tsutomu
公开号:US20100234609A1
公开(公告)日:2010-09-16
Provided are a compound represented by Formula (I):
wherein R
1
, R
2
, R
3
, and R
4
are each independently selected from a hydrogen atom, a C
1-6
alkyl group which may be substituted, a C
7-14
aralkyl group which may be substituted and —C(═O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f).
or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
We have developed a lanthanide/B(C6F5)3-promoted hydroboration reduction of indoles and quinolines with pinacolborane (HBpin). This reaction provides streamlined access to a range of nitrogen-containing compounds in moderate to excellent yields. Large-scale synthesis and further transformations to bioactive compounds indicate that the method has potential practical applications. Preliminary mechanistic
我们开发了一种镧系元素/B(C 6 F 5 ) 3促进的吲哚和喹啉与频那醇硼烷(HBpin)的硼氢化还原反应。该反应以中等至优异的收率提供了一系列含氮化合物的简化获取。大规模合成和进一步转化为生物活性化合物表明该方法具有潜在的实际应用。初步机理研究表明,胺添加剂促进吲哚硼烷中间体的形成,并且镧系元素/B(C 6 F 5 ) 3促进的硼氢化还原是通过吲哚硼烷中间体与 HBpin 和原位形成的 BH 3物质的硼氢化反应进行的,然后是原脱硼过程。
FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES
申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
公开号:EP2048152A1
公开(公告)日:2009-04-15
Provided are a compound represented by Formula (I):
wherein R1, R2, R3, and R4 are each independently selected from a hydrogen atom, a C1-6 alkyl group which may be substituted, a C7-14 aralkyl group which may be substituted and -C(=O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f).
, or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.